Publications by authors named "Partanen Anu"

Claim this Profile
I
Incidence and Mortality of Mycosis Fungoides and Sezary Syndrome: A Nationwide Registry Study in Finland.
Anu Partanen, Marjaana Häyrinen, Milla E L Kuusisto, Anna Anttalainen, Liisa Ukkola-Vuoti

Acta Derm Venereol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Graft-versus-tumor effect in autologous setting: fact or fallacy?
Anu Partanen, Tuure Kinnunen, Esa Jantunen

Leuk Lymphoma· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nodal peripheral T-cell lymphoma in Finland between 2007 and 2019: Incidence, late morbidity and survival.
Anu Partanen, Aino Rönkä, Anna Anttalainen, Liisa Ukkola-Vuoti, Iiro Toppila

Br J Haematol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of treatment delay of multiple myeloma bone disease on later myeloma-related skeletal events and outcome.
Eskelinen Veera, Niemi Pauli, Partanen Anu, Kangas Jaakko, E L Kuusisto Milla

J Bone Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching From Standard to Extended Half-Life Coagulation Factor Replacement in Haemophilia: Clinical Outcomes and Costs of Care in Finland.
Mirkka Koivusalo, Timea Szanto, Tuomas Kovalainen, Aino Vesikansa, Outi Laine, Anu Partanen

Haemophilia· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increasing incidence and prevalence of Hodgkin's lymphoma in Finland: a population-based registry study.
Tessa Antikainen, Noora Hannuksela, Anna Anttalainen, Anu Partanen, Aino Rönkä

Eur J Public Health· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Capillary Sampling Enables Venetoclax Concentration Measurement in Acute Myeloid Leukaemia Within Academic Multicentre Trial.
Sari Kytölä, Mika Kurkela, Johanna I Kiiski, Ida Vänttinen, Tanja Ruokoranta, Anu Partanen

Basic Clin Pharmacol Toxicol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of treatment practices and outcomes in multiple myeloma during 2013-2022: a Finnish real world registry study.
Anu Partanen, Marika Waltari, Johanna Vikkula, Riikka Mattila, Katja Närhi

Acta Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A real-world study on the impact of infection load on mortality in multiple myeloma patients in Finland.
Anna Anttalainen, Essi Havula, Kai Kysenius, Iiro Toppila, Tatu Miettinen, Anu Partanen

Ann Hematol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autograft composition and outcome-towards an optimal graft?
Esa Jantunen, Antti Turunen, Anu Partanen

Cytotherapy· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Satisfactory outcomes following a second autologous hematopoietic cell transplantation for multiple myeloma in poor stem cell mobilizers: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
Matjaz Sever, Joanna Drozd-Sokolowska, Luuk Gras, Linda Koster, Frantisek Folber, Anu Partanen

Bone Marrow Transplant· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trial.
Sari Kytölä, Ida Vänttinen, Tanja Ruokoranta, Anu Partanen, Annasofia Holopainen

Blood· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Comorbidities and survival of multiple myeloma patients diagnosed in Finland between 2000 and 2021.
Kai Kysenius, Anna Anttalainen, Iiro Toppila, Tatu Miettinen, Mariann Lassenius, Anu Partanen

Ann Hematol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comorbidities and survival of multiple myeloma patients diagnosed in Finland between 2000 and 2021.
Kai Kysenius, Anna Anttalainen, Iiro Toppila, Tatu Miettinen, Mariann Lassenius, Anu Partanen

Ann Hematol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival of patients with classical Hodgkin lymphoma in Finland: a national population-based analysis.
Noora Hannuksela, Anu Partanen, Anna Anttalainen, Liisa Ukkola-Vuoti, Iiro Toppila

Blood Cancer J· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-Line Combination with Proteasome Inhibitor-Based Treatment and Zoledronic Acid Is Effective in Reducing Later Fractures in Multiple Myeloma Irrespective of Multiple Myeloma Bone Disease at Diagnosis.
Veera Eskelinen, Elise Nivakoski, Kirsi Launonen, Anu Partanen, Sakari Kakko

Hematol Rep· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive Factors for Early Immune Recovery in NHL Patients after Autologous Transplantation: A Multicenter Prospective Study.
Anu Partanen, Antti Turunen, Outi Kuittinen, Hanne Kuitunen, Pentti Mäntymaa

Cancers (Basel)· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of plerixafor use in the mobilization of blood grafts for autologous hematopoietic cell transplantation.
Esa Jantunen, Antti Turunen, Ville Varmavuo, Anu Partanen

Transfusion· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group.
Anu Partanen, Anders Waage, Valdas Peceliunas, Fredrik Schjesvold, Pekka Anttila, Anu Marttila, Anu Sikiö

Cancers (Basel)· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loss of CD34 Cells and Effect of the Number of Viable Cryopreserved CD34 Cells in the Infused Blood Grafts on Hematologic Recovery, Progression-Free Survival and Overall Survival in NHL Patients After Autologous Stem Cell Transplantation.
Anu Partanen, Antti Turunen, Jaakko Valtola, Marja Pyörälä, Outi Kuittinen

Clin Lymphoma Myeloma Leuk· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD34 Cell Mobilization, Autograft Cellular Composition and Outcome in Mantle Cell Lymphoma Patients.
Antti Samuli Turunen, Outi Kuittinen, Hanne Kuitunen, Kaija Vasala, Karri Penttilä, Anu Partanen

Transfus Med Hemother· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mobilization Strategies in Myeloma Patients Intended for Autologous Hematopoietic Cell Transplantation.
Esa Jantunen, Anu Partanen, Antti Turunen, Ville Varmavuo, Raija Silvennoinen

Transfus Med Hemother· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia.
Heikki Kuusanmäki, Sari Kytölä, Ida Vänttinen, Tanja Ruokoranta, Amanda Ranta, Anu Partanen

Haematologica· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deep Immune Profiling of Multiple Myeloma at Diagnosis and under Lenalidomide Maintenance Therapy.
Sini Luoma, Philipp Sergeev, Komal Kumar Javarappa, Tiina J Öhman, Markku Varjosalo, Anu Partanen

Cancers (Basel)· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood-Brain Barrier Disruption (BBBD)-Based Immunochemotherapy for Primary Central Nervous System Lymphoma (PCNSL), Early Results of a Phase II Study.
Hanne K Kuitunen, Aino L K Rönkä, Eila M Sonkajärvi, Juha-Matti Isokangas, Marja Pyörälä, Anu E Partanen

Cancers (Basel)· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis